Xact Kapitalforvaltning AB lowered its position in Catalent Inc (NYSE:CTLT) by 9.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,390 shares of the company’s stock after selling 2,800 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Catalent were worth $854,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Three Peaks Capital Management LLC grew its stake in shares of Catalent by 15.0% during the 4th quarter. Three Peaks Capital Management LLC now owns 62,935 shares of the company’s stock worth $1,962,000 after purchasing an additional 8,197 shares during the period. Arizona State Retirement System grew its stake in shares of Catalent by 1.4% during the 4th quarter. Arizona State Retirement System now owns 104,339 shares of the company’s stock worth $3,253,000 after purchasing an additional 1,471 shares during the period. First Bank & Trust grew its stake in shares of Catalent by 13.9% during the 4th quarter. First Bank & Trust now owns 4,600 shares of the company’s stock worth $143,000 after purchasing an additional 563 shares during the period. Quantamental Technologies LLC acquired a new stake in shares of Catalent during the 4th quarter worth approximately $47,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Catalent by 21.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,996 shares of the company’s stock worth $312,000 after purchasing an additional 1,784 shares during the period. 97.95% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have recently commented on CTLT. Zacks Investment Research raised shares of Catalent from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a research note on Wednesday, February 6th. ValuEngine cut shares of Catalent from a “buy” rating to a “hold” rating in a research note on Tuesday, November 6th. Morgan Stanley set a $46.00 price objective on shares of Catalent and gave the stock a “buy” rating in a research note on Monday, December 3rd. Robert W. Baird began coverage on shares of Catalent in a research note on Thursday, November 15th. They set an “outperform” rating on the stock. Finally, TheStreet cut shares of Catalent from a “b-” rating to a “c+” rating in a research note on Wednesday, November 7th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $47.13.
Catalent stock traded down $0.02 during trading on Monday, reaching $39.71. The company had a trading volume of 2,964 shares, compared to its average volume of 1,009,348. Catalent Inc has a 1-year low of $29.23 and a 1-year high of $46.43. The stock has a market capitalization of $5.78 billion, a P/E ratio of 24.85, a P/E/G ratio of 2.18 and a beta of 1.66. The company has a debt-to-equity ratio of 1.36, a quick ratio of 1.63 and a current ratio of 2.08.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.08. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The firm had revenue of $623.00 million for the quarter, compared to analysts’ expectations of $608.38 million. During the same quarter last year, the company earned $0.45 EPS. The firm’s revenue for the quarter was up 2.8% compared to the same quarter last year. Sell-side analysts predict that Catalent Inc will post 1.69 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.thelincolnianonline.com/2019/02/11/catalent-inc-ctlt-stake-decreased-by-xact-kapitalforvaltning-ab.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NYSE:CTLT).
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.